NovaBridge Biosciences (NBP) Chief BD Officer Cao Sean Wuxiong Sells Shares

What Happened
Cao Sean Wuxiong, Chief Business Development Officer of NovaBridge Biosciences (NBP), reported a sale on 2026-09-09 of 46,947 ADSs (representing approximately 107,978 ordinary shares) for total proceeds of about $79,904. The filing reports a per‑ordinary‑share amount of $0.74; the ADS-level converted sales price is reported as $1.6908. This sale was made in connection with the partial vesting of a restricted stock unit award and was used solely to satisfy tax withholding obligations.

Key Details

• Transaction date: 2026-09-09; Form 4 filed 2026-09-11 (within normal Form 4 deadline).
• Amount sold: 46,947 ADSs, representing ≈107,978 ordinary shares.
• Reported price: $0.74 per ordinary share (converted ADS price reported as $1.6908).
• Proceeds: approximately $79,904.
• Reason (footnote): Sale executed solely to satisfy tax withholding on RSU vesting (vested 2026-09-03).
• Reported securities are ADSs (Footnote: each 10 ADSs represent 23 ordinary shares).
• Shares owned after the transaction: not specified in the provided filing.

Context
This was a tax-withholding sale tied to RSU vesting (routine for insiders) rather than an opportunistic market sale for cash or a purchase signaling bullish conviction. The filing clarifies ADS/ordinary‑share conversion; ADSs can represent multiple ordinary shares, which is why both ADS and ordinary‑share counts are reported.